Ulinastatin

Generic Name
Ulinastatin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
80449-31-6
Unique Ingredient Identifier
OR3S9IF86U
Background

Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery

Phase 4
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: placebo
Drug: ulinastatin
First Posted Date
2012-01-26
Last Posted Date
2012-01-26
Lead Sponsor
Konkuk University Medical Center
Target Recruit Count
26
Registration Number
NCT01518569
Locations
🇰🇷

Konkuk University Medical Center, Seoul, Korea, Republic of

Ulinastatin in Inhalation Lung Injury

First Posted Date
2011-02-01
Last Posted Date
2011-02-01
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
120
Registration Number
NCT01287806
Locations
🇨🇳

304 hospital of PLA, Beijin, Beijin, China

Ulinastatin in Severe Acute Pancreatitis

Phase 4
Suspended
Conditions
Pancreatitis
Interventions
Drug: placebo
Drug: ulinastatin
First Posted Date
2010-05-28
Last Posted Date
2018-01-17
Lead Sponsor
Techpool Bio-Pharma Co., Ltd.
Target Recruit Count
252
Registration Number
NCT01132521
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

🇨🇳

Wuhan Union Hospital of China, Wuhan, Hubei, China

🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

and more 3 locations

Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery

Not Applicable
Completed
Conditions
Hemostasis
Interventions
Drug: Saline Solution
Drug: Ulinastatin
Drug: Tranexamic Acid
First Posted Date
2010-02-02
Last Posted Date
2019-02-05
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
426
Registration Number
NCT01060189
Locations
🇨🇳

Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC, Beijing, Beijing, China

Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Phase 4
Completed
Conditions
Abnormal Aortic Valve
Interventions
Drug: ulinastatin
First Posted Date
2009-07-23
Last Posted Date
2011-05-27
Lead Sponsor
Yonsei University
Registration Number
NCT00944385
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy